Prl3d1 Antibody

What is Prl3d1 and why is it important in developmental biology research?

Prl3d1 (Prolactin 3d1), also known as placental lactogen 1 (PL-1), is a protein specifically expressed in parietal trophoblast giant cells (P-TGCs) in the developing placenta. Its importance lies in its role as a definitive marker for distinguishing trophoblast giant cells from other trophoblast cell populations . When conducting developmental biology research, particularly studies focusing on placental development and function, Prl3d1 serves as a critical marker for identifying and tracking P-TGCs. This specificity makes Prl3d1 antibodies valuable tools for investigating placental morphogenesis, implantation processes, and pregnancy-related disorders in animal models.

What types of Prl3d1 antibodies are available and how do they differ?

Prl3d1 antibodies are available in several formats with different characteristics:

The choice between these antibody types depends on your experimental goals. Polyclonal antibodies, like those offered by several suppliers, provide high sensitivity by recognizing multiple epitopes but may have batch-to-batch variation . Monoclonal antibodies offer consistent specificity for a single epitope, making them ideal for quantitative applications but potentially less sensitive than polyclonals . For multicolor imaging experiments, conjugated antibodies eliminate the need for secondary antibodies, simplifying protocols and reducing background.

How do I determine the appropriate application for my Prl3d1 antibody?

To determine the most suitable application for your Prl3d1 antibody:

• Review validation data from suppliers: Examine application-specific validation data provided by manufacturers, including Western blot bands, IHC images, or flow cytometry plots .

• Consider your experimental goals:

  • For protein localization in tissue sections, select antibodies validated for IHC or IF

  • For protein quantification, choose antibodies validated for Western blot or ELISA

  • For cell sorting/analysis, select antibodies validated for flow cytometry

• Perform pilot experiments: Test the antibody in your specific experimental setup using appropriate positive controls (such as placental tissue) and negative controls (tissues not expressing Prl3d1) .

• Optimize conditions: Adjust antibody concentration, incubation times, and detection methods to achieve optimal signal-to-noise ratio.

The application range for most Prl3d1 antibodies includes Western blotting, ELISA, immunohistochemistry, and immunofluorescence, with specific optimization required for each technique .

What are the optimal protocols for using Prl3d1 antibodies in immunohistochemistry?

When using Prl3d1 antibodies for immunohistochemistry, follow these methodological steps for optimal results:

• Tissue preparation:

  • Fix tissues in 4% paraformaldehyde for 24 hours

  • Process and embed in paraffin using standard protocols

  • Section at 5-7 μm thickness

• Antigen retrieval:

  • Heat-mediated antigen retrieval is critical for Prl3d1 detection

  • Use EDTA buffer (pH 8.0) or citrate buffer (pH 6.0)

  • Heat at 95-98°C for 20 minutes in a water bath or pressure cooker

• Blocking and antibody incubation:

  • Block with 5-10% normal serum from the same species as the secondary antibody

  • Use Prl3d1 antibody at dilutions between 1:50-1:500 (optimize based on your specific antibody)

  • Incubate at 4°C overnight for strongest specific signal

• Detection and visualization:

  • Use appropriate HRP-conjugated secondary antibody

  • Develop with DAB or other suitable chromogen

  • Counterstain with hematoxylin for nuclear visualization

• Controls:

  • Include placental tissue sections as positive controls

  • Include secondary-only controls to assess background

  • For mouse antibodies on mouse tissues, use mouse-on-mouse blocking kits to reduce background

This protocol has been validated for detecting Prl3d1 in placental tissue, particularly in the parietal trophoblast giant cell layer .

How should I optimize Western blot protocols for Prl3d1 detection?

For optimal Western blot detection of Prl3d1, follow these methodological steps:

• Sample preparation:

  • Extract proteins from placental tissue or cultured trophoblast cells using RIPA buffer with protease inhibitors

  • Determine protein concentration (BCA or Bradford assay)

  • Denature samples in Laemmli buffer with β-mercaptoethanol at 95°C for 5 minutes

• Gel electrophoresis and transfer:

  • Load 20-40 μg protein per lane on 10-12% SDS-PAGE gels

  • Transfer to PVDF membrane at 100V for 60-90 minutes in cold transfer buffer

  • Verify transfer efficiency with Ponceau S staining

• Antibody incubation:

  • Block membrane with 5% non-fat dry milk in TBST for 1 hour at room temperature

  • Incubate with Prl3d1 antibody at 1:500-1:2000 dilution overnight at 4°C

  • Wash extensively with TBST (3 × 10 minutes)

  • Incubate with appropriate HRP-conjugated secondary antibody (1:5000-1:10000) for 1 hour at room temperature

• Detection considerations:

  • Use enhanced chemiluminescence (ECL) detection reagents

  • Expected molecular weight for Prl3d1 is approximately 25 kDa

  • For weak signals, consider using more sensitive detection systems or signal enhancers

• Controls and troubleshooting:

  • Include mouse pituitary tissue lysate as positive control

  • Include loading control (β-actin, GAPDH) on the same membrane

  • If detecting multiple bands, optimize primary antibody concentration and washing steps

When analyzing Western blot results, note that Prl3d1 may show slight variations in molecular weight due to species differences or post-translational modifications .

What are the key considerations for ELISA development using Prl3d1 antibodies?

When developing an ELISA for Prl3d1 detection, consider these methodological aspects:

• Assay format selection:

  • Sandwich ELISA: Requires two antibodies recognizing different epitopes

  • Indirect ELISA: Uses a single antibody but may have lower specificity

  • Competitive ELISA: Useful for small samples or low abundance targets

• Protocol optimization:

  • Coating concentration: Test 1-10 μg/ml of capture antibody in carbonate buffer (pH 9.6)

  • Blocking: Use 1-5% BSA or non-fat dry milk in PBS

  • Sample dilution: Prepare a dilution series to determine optimal concentration range

  • Detection antibody: If using sandwich format, optimize concentration (typically 0.5-2 μg/ml)

  • Incubation times: Typically 1-2 hours at room temperature or overnight at 4°C

• Standard curve preparation:

  • Use recombinant Prl3d1 protein at concentrations ranging from 0-1000 pg/ml

  • Include at least 7-8 points for accurate curve fitting

  • Prepare standards in the same buffer as samples to minimize matrix effects

• Validation parameters:

  • Determine lower limit of detection (typically 10-50 pg/ml for well-optimized assays)

  • Assess intra- and inter-assay variability (CV should be <15%)

  • Test recovery by spiking known concentrations into sample matrix

  • Evaluate parallelism between standard curve and serial dilutions of samples

• Species considerations:

  • Ensure antibodies recognize the target species (mouse, human, rat) as specified in product documentation

  • Be aware that cross-reactivity between species varies among different antibody products

Several commercial suppliers offer Prl3d1 antibodies validated for ELISA applications, primarily for mouse samples, though some have cross-reactivity with human and rat Prl3d1 .

How do I select Prl3d1 antibodies with appropriate species reactivity for my research?

Selecting Prl3d1 antibodies with appropriate species reactivity requires careful consideration of several factors:

• Target species alignment analysis:

  • Prl3d1 sequence homology varies significantly across species

  • Human and non-human primate Prl3d1 share high homology, but diverge significantly from rodent variants

  • Some antibodies (like PL 200,031 and PL 200,039) cross-react with non-human primate PRL but not with rodent PRL

• Epitope mapping considerations:

  • Examine which region of Prl3d1 the antibody targets

  • N-terminal regions tend to have greater species variation than C-terminal regions

  • Request epitope information from manufacturers if not provided in technical specifications

• Validation evidence assessment:

  • Review species reactivity data provided by manufacturers

  • Look for images of Western blots showing detection in your species of interest

  • Check for peer-reviewed publications using the antibody in your target species

• Species-specific recommendations:

  • For mouse studies: Multiple validated antibodies are available with confirmed mouse reactivity

  • For human studies: Fewer options exist, but some antibodies show human reactivity

  • For comparative studies: Consider antibodies validated for multiple species if cross-species comparison is needed

Using species-inappropriate antibodies is a common source of false-negative results in Prl3d1 research, so validation in your specific model system is essential .

What is the likelihood of cross-reactivity between Prl3d1 antibodies and other prolactin family members?

The prolactin family includes multiple members with structural similarities, creating potential for cross-reactivity:

• Structural homology analysis:

  Prolactin Family Member	Homology to Prl3d1	Cross-Reactivity Risk
  Prl3b1 (PL-2)	High	Significant
  Prl2c2 (PLF)	Moderate	Moderate
  PRL (Pituitary)	Low to moderate	Low to moderate
  Growth Hormone	Low	Minimal

• Documented cross-reactivity patterns:

  • Many Prl3d1 antibodies show some degree of cross-reactivity with Prl3b1 due to structural similarities

  • Some antibodies are specifically designed to avoid cross-reactivity with other prolactin family members

  • PRL mAbs like PL 200,031 and PL 200,039 are selective for human PRL and do not inhibit other hPRLR agonists such as human growth hormone or placental lactogen

• Cross-reactivity testing methods:

  • Western blot analysis using recombinant proteins for each family member

  • Competitive binding assays to assess relative affinities

  • Immunohistochemistry using tissues with known expression patterns of different family members

• Minimizing cross-reactivity concerns:

  • Select monoclonal antibodies for highest specificity when distinguishing between family members

  • Use positive and negative control tissues with known expression patterns

  • Confirm findings with secondary detection methods (RT-PCR, in situ hybridization)

Understanding these cross-reactivity patterns is particularly important when studying placental development, as multiple prolactin family members are co-expressed in different trophoblast populations .

How can Prl3d1-Cre mouse models be utilized for lineage tracing and conditional gene deletion?

Prl3d1-Cre mouse models offer powerful tools for studying placental development through lineage tracing and conditional gene deletion:

• Available Prl3d1-Cre mouse lines:

  • Prl3d1tm1(cre)Gle (Pl1-Cre): Expresses Cre recombinase specifically in parietal trophoblast giant cells (P-TGCs)

  • Prl3d1-iCre: Expresses improved Cre recombinase under endogenous prl3d1 control

• Lineage tracing applications:

  • When crossed with reporter lines (like Rosa26-mT/mG or Rosa26-LacZ), Prl3d1-Cre mice enable visualization of cells derived from Prl3d1-expressing progenitors

  • This approach has revealed that P-TGCs arise from two sources: primary differentiation from trophectoderm and secondary differentiation from ectoplacental cone precursors

  • Temporal dynamics of P-TGC development can be studied using inducible Cre systems

• Conditional gene deletion methodology:

  • Cross Prl3d1-Cre mice with mice carrying loxP-flanked ("floxed") genes of interest

  • This allows P-TGC-specific deletion of target genes

  • Example application: Deletion of GATA2 and GATA3 transcription factors in P-TGCs using Prl3d1-Cre led to embryonic lethality and revealed their role in placental development

• Technical considerations:

  • Validate Cre expression pattern using reporter mice before experimental studies

  • Consider potential ectopic expression in tissues other than P-TGCs

  • Use laser capture microdissection to confirm gene deletion specifically in P-TGCs

  • Include Cre-negative littermates as essential controls

• Advanced applications:

  • Combine with single-cell RNA sequencing to identify transcriptional signatures of P-TGCs and their descendants

  • Use with optogenetic or chemogenetic tools for temporal control of P-TGC function

  • Integrate with in vivo imaging approaches to visualize P-TGC behavior in real time

This technology has provided critical insights into the non-autonomous signaling from primary parietal TGCs that maintain placental hematopoietic-angiogenic balance during development .

What are the latest advances in utilizing humanized antibodies against prolactin for potential therapeutic applications?

Recent advances in humanized antibodies against prolactin have opened new possibilities for therapeutic applications:

• Development of humanized PRL neutralizing antibodies:

  • PL 200,031 (human IgG1) and PL 200,039 (human IgG4) represent first-in-class humanized PRL neutralizing monoclonal antibodies

  • These antibodies demonstrate sub-nanomolar affinity for human PRL (hPRL)

  • They produce concentration-dependent and complete inhibition of hPRL signaling at the hPRL receptor (hPRLR)

• Selectivity profile:

  • These antibodies selectively target hPRL without inhibiting other hPRLR agonists such as human growth hormone or placental lactogen

  • They cross-react with non-human primate PRL but not with rodent PRL

  • This selectivity profile makes them valuable tools for specific targeting of PRL-mediated processes

• Pharmacokinetic properties:

  • Both antibodies show long clearance half-lives after intravenous administration in FcRn-humanized mice

  • They differ in binding affinities to Fcγ receptors, consistent with their IgG1 vs. IgG4 isotypes

  • These properties are advantageous for potential therapeutic applications requiring prolonged suppression of PRL activity

• Proof-of-concept studies:

  • The murine parental antibody (PL 200,019) fully blocked stress-induced and PRL-dependent pain behaviors in female PRL-humanized mice

  • This provides preclinical proof-of-efficacy for PRL mAbs in mechanisms relevant to female-specific pain conditions

  • These findings are particularly relevant given the higher prevalence of pain syndromes in women

• Methodological considerations for translational research:

  • Humanized mouse models expressing human PRL are essential for preclinical validation

  • Careful assessment of potential side effects on lactation and reproductive function is necessary

  • Biomarker development to identify patients most likely to benefit from anti-PRL therapy

These advances highlight the potential for targeting PRL in conditions with sex-specific manifestations, particularly functional pain syndromes with high female:male prevalence ratios .

How can single-cell transcriptomics be integrated with Prl3d1 antibody-based approaches to understand placental development?

Integrating single-cell transcriptomics with Prl3d1 antibody-based approaches offers powerful insights into placental development:

• Complementary methodological approach:

  • Single-cell RNA-seq provides comprehensive transcriptional profiles but lacks spatial context

  • Prl3d1 antibody-based immunostaining provides precise spatial localization but with limited molecular resolution

  • Integration creates a spatially-resolved molecular map of placental development

• Experimental design for integration:

  • Perform single-cell RNA-seq on dissociated placental cells to identify cell clusters

  • Use Prl3d1 expression as a marker to identify P-TGC clusters

  • Validate cluster identity with immunohistochemistry using Prl3d1 antibodies

  • Apply spatial transcriptomics or laser capture microdissection to link transcriptional states with anatomical locations

• Advanced analytical approaches:

  • Trajectory analysis to track differentiation paths of Prl3d1-expressing cells

  • Receptor-ligand interaction analysis to identify signaling between P-TGCs and other placental cell types

  • Gene regulatory network reconstruction to understand transcriptional control of P-TGC differentiation

• Practical implementation example:

  • Research has identified distinct trophoblast clusters through single-cell analysis, including cluster 33 showing co-expression of Prl3d1, Gata2, and Gata3

  • This cluster was identified as the TGC-cluster through correlation with immunohistochemistry data

  • Integration revealed that loss of Gata2 and Gata3 in Prl3d1-expressing cells affected other trophoblast populations, identifying non-autonomous effects

• Technical considerations:

  • Ensure antibodies are compatible with tissue processing methods used for RNA analysis

  • Consider sequential immunostaining and RNA detection on the same section

  • Account for potential artifacts from tissue dissociation in single-cell data

  • Use multiple antibodies targeting different epitopes to ensure robust identification

This integrated approach has revealed novel mechanisms by which non-autonomous signaling from primary parietal TGCs maintains placental hematopoietic-angiogenic balance during development .

What strategies can resolve non-specific binding issues when using Prl3d1 antibodies?

Non-specific binding is a common challenge with Prl3d1 antibodies. Here are methodological approaches to resolve these issues:

• Optimization of blocking conditions:

  • Test different blocking agents: 5-10% normal serum (from secondary antibody species), 3-5% BSA, commercial blocking solutions

  • Extend blocking time to 1-2 hours at room temperature

  • Add 0.1-0.3% Triton X-100 to blocking buffer to improve penetration

  • Include 0.1% cold fish skin gelatin to reduce hydrophobic interactions

• Antibody dilution and incubation adjustments:

  • Perform a dilution series (e.g., 1:50, 1:100, 1:200, 1:500) to determine optimal concentration

  • Consider longer incubation at lower concentration (overnight at 4°C)

  • Add 0.1-0.5% non-ionic detergent (Tween-20) to antibody diluent

  • Pre-adsorb antibody with tissue powder from negative control tissue

• Additional washing steps modifications:

  • Increase washing duration (6-8 washes of 10 minutes each)

  • Use higher salt concentration (0.5M NaCl) in wash buffer

  • Add 0.05-0.1% Tween-20 to wash buffer

  • Incorporate a high-stringency wash step using 0.1% SDS

• Control experiments to identify sources of non-specificity:

  • Secondary-only controls to assess background from secondary antibody

  • Isotype controls to evaluate non-specific binding from primary antibody class

  • Absorption controls using recombinant Prl3d1 protein to confirm specificity

  • Tissue-negative controls (tissues known not to express Prl3d1)

• Application-specific considerations:

  • For Western blot: Increase blocking time and concentration, test alternative membrane types

  • For IHC/IF: Use Fab fragments to block endogenous immunoglobulins, particularly critical when using mouse antibodies on mouse tissues

  • For flow cytometry: Include viability dye to exclude dead cells that often bind antibodies non-specifically

These approaches have successfully reduced non-specific binding in various applications using Prl3d1 antibodies from multiple suppliers .

How should researchers properly store and handle Prl3d1 antibodies to maintain optimal performance?

Proper storage and handling of Prl3d1 antibodies is essential for maintaining their performance over time:

• Long-term storage recommendations:

  • Store antibodies at -20°C to -70°C for maximum stability (up to 12 months)

  • Avoid repeated freeze-thaw cycles by preparing small aliquots upon receipt

  • For glycerol-containing preparations (typically 50% glycerol), storage at -20°C is sufficient

  • Keep desiccant in storage containers to prevent moisture accumulation

• Working stock preparation and handling:

  • When preparing working dilutions, use high-quality, sterile buffers (PBS or TBS)

  • Add preservatives to working stocks (0.02% sodium azide, 0.05% thimerosal, or proprietary stabilizers)

  • Store working dilutions at 2-8°C for up to 1 month under sterile conditions

  • Do not store diluted antibody in polystyrene tubes (use polypropylene)

  • Avoid exposure to strong light, particularly for fluorochrome-conjugated antibodies

• Transport and temporary handling:

  • Use insulated containers with ice packs when transporting antibodies

  • Minimize time at room temperature during experiments

  • Return to appropriate storage temperature promptly after use

  • Never leave antibodies at room temperature overnight

• Performance monitoring:

  • Include positive controls in each experiment to monitor antibody performance over time

  • Document lot numbers and dates of first use

  • Consider preparing a reference sample to test new lots against previous ones

  • Keep records of antibody performance to detect degradation

• Reconstitution of lyophilized antibodies:

  • Use sterile, molecular-grade water or recommended buffer

  • Gently mix by rotating or inverting; avoid vigorous vortexing

  • Allow complete dissolution before aliquoting (typically 5-10 minutes)

  • Process the entire preparation in one session to avoid repeated exposure to ambient conditions

Following these guidelines will help maintain antibody performance throughout the expected validity period (typically 12 months) .

What are the most effective positive and negative controls for validating Prl3d1 antibody specificity?

Proper controls are essential for validating Prl3d1 antibody specificity in research applications:

• Positive tissue controls:

  • Placental tissue (E8.5-E12.5 mouse placenta): Contains parietal trophoblast giant cells with high Prl3d1 expression

  • Pituitary tissue: Contains prolactin-expressing cells useful for cross-reactivity assessment

  • Expression system controls: HEK293 or CHO cells transfected with Prl3d1 expression vector

• Negative tissue controls:

  • Adult liver, kidney, or heart tissues: Typically lack Prl3d1 expression

  • Placental tissues from later developmental stages (E16.5+): Reduced Prl3d1 expression as pregnancy progresses

  • Tissues from Prl3d1 knockout mice, if available

• Antibody-specific controls:

  • Peptide competition/blocking: Pre-incubate antibody with excess recombinant Prl3d1 or immunizing peptide

  • Isotype control: Use matched isotype antibody from same species at identical concentration

  • Secondary-only control: Omit primary antibody but include all other steps

  • Concentration gradient: Test multiple antibody dilutions to demonstrate dose-dependent signal

• Molecular validation approaches:

  • siRNA knockdown: Reduce Prl3d1 expression in cultured trophoblast cells

  • Western blot correlation: Confirm that IHC signal correlates with presence of band at expected molecular weight (25 kDa)

  • Correlation with mRNA expression: Use in situ hybridization with Prl3d1-specific probes on adjacent sections

• Advanced validation methods:

  • Mass spectrometry verification of immunoprecipitated protein

  • Dual-labeling with two antibodies against different Prl3d1 epitopes

  • Comparison of results across multiple detection platforms (IHC, WB, IF)

  • Cross-validation using gene editing approaches (CRISPR/Cas9)

Implementing these controls systematically provides robust validation of Prl3d1 antibody specificity and ensures reliable research outcomes .

What emerging technologies are likely to impact Prl3d1 antibody-based research in the near future?

Several emerging technologies are poised to transform Prl3d1 antibody-based research:

• Spatial transcriptomics integration:

  • Technologies like Visium, MERFISH, and Slide-seq allow simultaneous visualization of Prl3d1 protein (via antibodies) and transcriptome-wide gene expression

  • This integration will provide unprecedented insights into the molecular heterogeneity of Prl3d1-expressing cells within their native tissue environment

  • Spatial context will help elucidate how Prl3d1-expressing cells interact with neighboring cell populations

• Advanced antibody engineering platforms:

  • Recombinant antibody technologies allowing precise epitope targeting

  • Nanobodies and single-chain antibodies offering improved tissue penetration

  • Multispecific antibodies enabling simultaneous targeting of Prl3d1 and related proteins

  • CRISPR-based epitope tagging of endogenous Prl3d1 to circumvent antibody specificity issues

• 3D tissue imaging and analysis:

  • Tissue clearing techniques (CLARITY, iDISCO, CUBIC) compatible with Prl3d1 antibodies

  • Light-sheet microscopy enabling whole-organ 3D visualization of Prl3d1 expression

  • Computational image analysis tools for quantitative assessment of 3D expression patterns

• Single-cell proteomics approaches:

  • Mass cytometry (CyTOF) incorporating Prl3d1 antibodies for high-dimensional protein profiling

  • Single-cell Western blotting to assess Prl3d1 heterogeneity at protein level

  • Proximity ligation assays to study Prl3d1 interactions with binding partners in situ

• In vivo antibody-based approaches:

  • Intravital microscopy with fluorescently-labeled Prl3d1 antibodies

  • Antibody-based biosensors for real-time monitoring of Prl3d1 secretion

  • Therapeutic applications of engineered anti-prolactin antibodies for female-specific pain conditions

These technologies will enable researchers to move beyond static analysis of Prl3d1 expression to understand its dynamic regulation and function in development and disease states.

What are the key considerations when reporting Prl3d1 antibody usage in scientific publications?

When reporting Prl3d1 antibody usage in scientific publications, researchers should include the following key information to ensure reproducibility and transparency:

• Comprehensive antibody identification:

  • Full catalog number and manufacturer/supplier name

  • Clone number for monoclonal antibodies (e.g., clone 207518)

  • Host species and antibody isotype (e.g., Rabbit IgG)

  • RRID (Research Resource Identifier) when available

  • Lot number (particularly important for polyclonal antibodies)

• Detailed methodological information:

  • Exact antibody dilution or concentration used (e.g., 1:500 or 2 μg/ml)

  • Buffer composition for antibody dilution

  • Incubation conditions (time, temperature)

  • Antigen retrieval method (for IHC/IF) including buffer composition and pH

  • Detection system specifications (secondary antibodies, visualization reagents)

• Validation procedures performed:

  • Description of positive and negative controls

  • Any validation experiments conducted (peptide blocking, knockout controls)

  • Citation of previous validation studies, if relying on them

  • Images of controls alongside experimental results

• Quantification and analysis methods:

  • Detailed description of quantification approach

  • Software used for image analysis

  • Blinding procedures for subjective assessments

  • Statistical methods applied to antibody-derived data

• Limitations and potential caveats:

  • Known cross-reactivity with other prolactin family members

  • Batch-to-batch variations observed, if any

  • Limitations of the detection method

  • Alternative interpretations of the findings